Table 1.
The results of binary logistic regression analysis for predictive models.
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |
| Gender | 0.957 | 0.688-1.331 | 0.882 | |||
| Age | 1.080 | 0.659-1.770 | 0.908 | |||
| VASARI | ||||||
| F1 | 1.036 | 0.857-1.252 | 0.922 | |||
| F2 | 1.541 | 0.926-2.565 | 0.465 | |||
| F3 | 0.916 | 0.645-1.301 | 0.787 | |||
| F4 | 1.255 | 0.831-1.895 | 0.652 | |||
| F5 | 0.946 | 0.722-1.240 | 0.897 | |||
| F6 | 1.178 | 0.885-1.568 | 0.736 | |||
| F7 | 0.933 | 0.691-1.260 | 0.807 | |||
| F8 | 2.036 | 1.029-4.029 | 0.046 | 1.136 | 0.986-1.309 | 0.088 |
| F9 | 1.252 | 0.836-1.875 | 0.688 | |||
| F10 | 0.853 | 0.492-1.479 | 0.162 | |||
| F11 | 1.461 | 0.896-2.382 | 0.507 | |||
| F12 | 0.952 | 0.757-1.197 | 0.776 | |||
| F13 | 1.281 | 0.853-1.924 | 0.439 | |||
| F14 | 3.638 | 1.088-12.165 | 0.029 | 2.152 | 1.029-4.501 | 0.036 |
| F15 | 1.109 | 0.905-1.371 | 0.786 | |||
| F16 | 1.266 | 0.932-1.720 | 0.409 | |||
| F17 | 0.899 | 0.673-1.201 | 0.533 | |||
| F18 | 1.426 | 0.811-2.507 | 0.427 | |||
| F19 | 1.058 | 0.957-1.170 | 0.456 | |||
| F20 | 1.436 | 0.913-2.259 | 0.221 | |||
| F21 | 3.895 | 1.120-13.546 | 0.011 | 2.487 | 1.094-5.654 | 0.026 |
| F22 | 0.895 | 0.616-1.300 | 0.436 | |||
| F23 | 1.127 | 0.882-1.440 | 0.649 | |||
| F24 | 2.587 | 1.031-6.491 | 0.035 | 1.195 | 0.992-1.440 | 0.062 |
| F25 | 1.225 | 0.894-1.679 | 0.587 | |||
| Rad-score | 13.661 | 3.688-50.603 | <0.001 | 18.604 | 4.257-81.303 | <0.001 |
CI, confidence interval; OR, odds ratio. VASARI, The Visually AcceSAble Rembrandt Images. F1: Tumor Location. F2: Side of Tumor Epicenter, F3: Eloquent Brain. F4: Enhancement Quality. F5: Proportion Enhancing. F6: Proportion nCET. F7: Proportion Necrosis. F8: Cyst(s). F9: Multifocal or Multicentric. F10: T1/FLAIR RATIO. F11: Thickness of enhancing margin. F12: Definition of the enhancing margin. F13: Definition of the non -enhancing margin. F14: Proportion of Edema. F15: Edema Crosses Midline. F16: Hemorrhage. F17: Diffusion. F18: Pial invasion. F19: Ependymal invasion. F20: Cortical involvement. F21: Deep White Matter Invasion. F22: nCET tumor Crosses Midline. F23: Enhancing tumor Crosses Midline. F24: Satellites. F25: Calvarial remodeling.